|Other Names||T-DM1, trastuzumab emtansine, trastuzumab-DM1,|
|Treatment By||IV - Injection|
|Treatment Form||Antibody-Drug Conjugate (ADC)|
|Inhibitor||HER2 Human Epidermal Growth Factor Receptor 2|
On February 22, 2013, the U.S. Food and Drug Administration approved of Kadcyla for the treatment of people with HER2-positive metastatic breast cancer.
This medication may help NF2 tumors, but it is not in trial because of the severe side effects of Kadcyla are life threatening. But, this medication was developed using a new method of combining chemical compounds. This new method will allow for an entirely new line of treatments that will result in better management of a wide variety of tumour issues.
Not to be confused with Trastuzumab (Herclon™ or Herceptin™).